KR102955585B1 - 에스. 아우레우스 클럼핑 인자 A(ClFA)에 지향되는 항체 - Google Patents
에스. 아우레우스 클럼핑 인자 A(ClFA)에 지향되는 항체Info
- Publication number
- KR102955585B1 KR102955585B1 KR1020217005010A KR20217005010A KR102955585B1 KR 102955585 B1 KR102955585 B1 KR 102955585B1 KR 1020217005010 A KR1020217005010 A KR 1020217005010A KR 20217005010 A KR20217005010 A KR 20217005010A KR 102955585 B1 KR102955585 B1 KR 102955585B1
- Authority
- KR
- South Korea
- Prior art keywords
- ser
- antibody
- antigen
- thr
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702762P | 2018-07-24 | 2018-07-24 | |
| US62/702,762 | 2018-07-24 | ||
| PCT/US2019/043254 WO2020023644A2 (en) | 2018-07-24 | 2019-07-24 | Antibody directed against s. aureus clumping factor a (clfa) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210035846A KR20210035846A (ko) | 2021-04-01 |
| KR102955585B1 true KR102955585B1 (ko) | 2026-04-21 |
Family
ID=67539640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217005010A Active KR102955585B1 (ko) | 2018-07-24 | 2019-07-24 | 에스. 아우레우스 클럼핑 인자 A(ClFA)에 지향되는 항체 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11155606B2 (enExample) |
| EP (1) | EP3840838A2 (enExample) |
| JP (2) | JP7525471B2 (enExample) |
| KR (1) | KR102955585B1 (enExample) |
| CN (2) | CN112672788B (enExample) |
| AU (1) | AU2019309366B2 (enExample) |
| BR (1) | BR112021001214A2 (enExample) |
| MX (1) | MX2021000889A (enExample) |
| TW (1) | TWI902669B (enExample) |
| WO (1) | WO2020023644A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2917360B1 (en) | 2012-11-06 | 2020-01-08 | Medlmmune, LLC | Antibodies to s. aureus surface determinants |
| DE102018115012A1 (de) | 2018-06-21 | 2019-12-24 | Carl Zeiss Microscopy Gmbh | Teilchenstrahlsystem |
| MX2021000889A (es) | 2018-07-24 | 2021-04-28 | Medimmune Llc | Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus. |
| WO2020076790A1 (en) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Antibodies directed against staphylococcus aureus leukotoxins |
| MX2021004173A (es) | 2018-10-09 | 2021-09-08 | Medimmune Llc | Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. |
| TWI743626B (zh) | 2019-01-24 | 2021-10-21 | 德商卡爾蔡司多重掃描電子顯微鏡有限公司 | 包含多束粒子顯微鏡的系統、對3d樣本逐層成像之方法及電腦程式產品 |
| DE102019008249B3 (de) | 2019-11-27 | 2020-11-19 | Carl Zeiss Multisem Gmbh | Teilchenstrahl-System mit einer Multistrahl-Ablenkeinrichtung und einem Strahlfänger, Verfahren zum Betreiben des Teilchenstrahl-Systems und zugehöriges Computerprogrammprodukt |
| IL324469A (en) * | 2023-05-09 | 2026-01-01 | Astrazeneca Ab | Anti-Pseudomonal bispecific antibodies with modified fc regions and methods of using them |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| WO2002072600A2 (en) * | 2001-01-26 | 2002-09-19 | Inhibitex, Inc. | Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| US20030226155A1 (en) | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| ATE458006T1 (de) | 2003-05-14 | 2010-03-15 | Kenta Biotech Ag | Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa |
| CN1324049C (zh) | 2003-08-04 | 2007-07-04 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗sars冠状病毒基因工程抗体 |
| US20050226878A1 (en) | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
| TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| JP2009539979A (ja) | 2006-06-12 | 2009-11-19 | ナビ バイオファーマシューティカルズ | ブドウ球菌感染症を治療および予防するための、α毒素の使用 |
| JP5675109B2 (ja) | 2007-02-20 | 2015-02-25 | アナプティスバイオ インコーポレイティッド | ライブラリーの生成方法及びその使用 |
| JP5718640B2 (ja) | 2007-08-21 | 2015-05-13 | アムジエン・インコーポレーテツド | ヒトｃ−ｆｍｓ抗原結合性タンパク質 |
| KR20100072228A (ko) | 2007-08-31 | 2010-06-30 | 유니버시티 오브 시카고 | 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물 |
| KR20110044991A (ko) | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | ＴＮＦ-α 길항제 다-표적 결합 단백질 |
| EP2208787A1 (en) | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| CN102387814A (zh) | 2009-01-29 | 2012-03-21 | 米迪缪尼有限公司 | 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用 |
| AU2010251156C1 (en) | 2009-05-18 | 2015-02-05 | Julius-Maximilians-Universitat Wurzburg | Antibodies or fragments thereof directed against a Staphylococcus aureus epitope of IsaA or IsaB |
| LT3444268T (lt) | 2010-05-05 | 2022-04-11 | New York University | Staphylococcus aureus leukocidinai, terapinės kompozicijos ir jų panaudojimo būdai |
| RS58190B2 (sr) | 2011-02-08 | 2021-08-31 | Medimmune Llc | Antitela koja specifično vezuju staphylococcus aureus alfa toksin i postupci njihove primene |
| EP3777885A1 (en) | 2011-06-19 | 2021-02-17 | New York University | Methods of treating and preventing staphylococcus aureus infections and associated conditions |
| US9962419B2 (en) | 2012-03-19 | 2018-05-08 | Tecnifar—Industria Tecnica Farmaceutica, S.A. Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA | Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections |
| ES2912267T3 (es) | 2012-11-06 | 2022-05-25 | Medimmune Llc | Métodos de tratamiento de enfermedades asociadas a S. aureus |
| EP2917360B1 (en) | 2012-11-06 | 2020-01-08 | Medlmmune, LLC | Antibodies to s. aureus surface determinants |
| CN105873946A (zh) | 2013-10-17 | 2016-08-17 | 阿尔萨尼斯生物科学有限责任公司 | 交叉反应性金黄色葡萄球菌抗体序列 |
| AU2014363987A1 (en) | 2013-12-09 | 2016-06-30 | Janssen Biotech, Inc. | Compositions and methods for phagocyte delivery of anti-staphylococcal agents |
| BR112016014163A2 (pt) | 2013-12-19 | 2018-01-09 | Arsanis Biosciences Gmbh | anticorpos direcionados contra a toxina lukgh (lukab) de staphylococcus aureus e as sequências de anticorpos, seu uso no tratamento ou no diagnóstico de infecção por s. aureus, as preparações farmacêuticas e para diagnóstico, os ácidos nucleicos que codificam os anticorpos, o paratopo isolado dos anticorpos e o epítopo conformacional isolado |
| JP6832709B2 (ja) | 2014-05-16 | 2021-02-24 | メディミューン，エルエルシー | 新生児Ｆｃ受容体結合が改変されて治療および診断特性が強化された分子 |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| AU2016249837A1 (en) | 2015-04-17 | 2017-09-28 | Arsanis Biosciences Gmbh | Anti-staphylococcus aureus antibody combination preparation |
| US20190077851A1 (en) | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
| MX2021000889A (es) | 2018-07-24 | 2021-04-28 | Medimmune Llc | Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus. |
| MX2021004173A (es) | 2018-10-09 | 2021-09-08 | Medimmune Llc | Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. |
| WO2020076790A1 (en) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Antibodies directed against staphylococcus aureus leukotoxins |
-
2019
- 2019-07-24 MX MX2021000889A patent/MX2021000889A/es unknown
- 2019-07-24 CN CN201980058857.XA patent/CN112672788B/zh active Active
- 2019-07-24 US US16/521,223 patent/US11155606B2/en active Active
- 2019-07-24 JP JP2021503901A patent/JP7525471B2/ja active Active
- 2019-07-24 CN CN202411220211.6A patent/CN119176871A/zh active Pending
- 2019-07-24 AU AU2019309366A patent/AU2019309366B2/en active Active
- 2019-07-24 EP EP19749544.3A patent/EP3840838A2/en active Pending
- 2019-07-24 WO PCT/US2019/043254 patent/WO2020023644A2/en not_active Ceased
- 2019-07-24 KR KR1020217005010A patent/KR102955585B1/ko active Active
- 2019-07-24 TW TW108126187A patent/TWI902669B/zh active
- 2019-07-24 BR BR112021001214-1A patent/BR112021001214A2/pt unknown
-
2021
- 2021-09-23 US US17/483,162 patent/US11970527B2/en active Active
-
2024
- 2024-03-28 JP JP2024053871A patent/JP7892714B2/ja active Active
- 2024-03-29 US US18/621,921 patent/US20240352098A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240352098A1 (en) | 2024-10-24 |
| WO2020023644A3 (en) | 2020-03-19 |
| TWI902669B (zh) | 2025-11-01 |
| CN119176871A (zh) | 2024-12-24 |
| CN112672788B (zh) | 2024-09-17 |
| AU2019309366A1 (en) | 2021-02-18 |
| CN112672788A (zh) | 2021-04-16 |
| TW202019956A (zh) | 2020-06-01 |
| EP3840838A2 (en) | 2021-06-30 |
| AU2019309366B2 (en) | 2025-06-05 |
| US11970527B2 (en) | 2024-04-30 |
| MX2021000889A (es) | 2021-04-28 |
| US20220073595A1 (en) | 2022-03-10 |
| WO2020023644A2 (en) | 2020-01-30 |
| JP7525471B2 (ja) | 2024-07-30 |
| BR112021001214A2 (pt) | 2021-04-27 |
| JP7892714B2 (ja) | 2026-07-21 |
| JP2021530244A (ja) | 2021-11-11 |
| CA3107463A1 (en) | 2020-01-30 |
| US20200048330A1 (en) | 2020-02-13 |
| US11155606B2 (en) | 2021-10-26 |
| KR20210035846A (ko) | 2021-04-01 |
| JP2024105229A (ja) | 2024-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11970527B2 (en) | Antibody directed against S. aureus clumping factor A (ClfA) | |
| AU2014363987A1 (en) | Compositions and methods for phagocyte delivery of anti-staphylococcal agents | |
| US20160244511A1 (en) | Cross-reactive staphylococcus aureus antibody sequences | |
| EP3083679B1 (en) | Antibodies directed against the lukgh (lukab) toxin of staphylococcus aureus and antibody sequences | |
| KR20170136637A (ko) | 항-스타필로코커스 아우레우스 항체 배합 제제 | |
| KR20210072057A (ko) | 항-황색포도상구균 항체의 조합 | |
| US20190062411A1 (en) | Mrka polypeptides, antibodies, and uses thereof | |
| CN113015745A (zh) | 针对金黄色葡萄球菌白细胞毒素的抗体 | |
| US20190077851A1 (en) | Methods of using anti-alpha toxin antibody | |
| KR20190064636A (ko) | 항-o1 항체 및 이의 용도 | |
| WO2013089877A2 (en) | Adjuvant therapy for staphylococcal infection with enterotoxin specific mabs | |
| RU2818805C2 (ru) | АНТИТЕЛО, НАПРАВЛЕННОЕ ПРОТИВ ФАКТОРА СЛИПАНИЯ А (ClfA) S. aureus | |
| KR20170137111A (ko) | 에스. 아우레우스의 면역글로불린 결합 단백질에 대해 지시된 항체 | |
| HK40009426A (zh) | 抗o1抗体及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| G15 | Pta requested |
Free format text: ST27 STATUS EVENT CODE: A-4-4-G10-G15-TAD-PA0102 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0102 | Application to register extension of term of patent right following delayed registration |
St.27 status event code: A-4-4-G10-G15-tad-PA0102 Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 120 |